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In the current issue of Critical Care, Opmeer and 
colleagues present an economic follow-up to their 
randomized clinical trial regarding on-demand versus 
planned relaparotomies for severe peritonitis [1]. In light 
of recent feverish debates surrounding healthcare reform 
in the United States, bending the cost curve has become 
a slogan with increasing popularity. Numerous health 
policy institutes have written briefs, many special 
editions of health services journals have been published, 
and multiple editorials in the US media have been put 
forth trying to explain what this phrase entails, and of 
course the solution. What does bending the cost curve 
mean, however, and how can we achieve it (or even begin 
to achieve it)?
Inevitably, both healthcare professionals and patients 
wish to achieve optimal patient outcomes within a system 
bound by limited resources. While we have always 
recognized the need for optimal outcomes, we are only 
now coming to grips with the limited resources. Many 
continue to debate what the etiology of our high 
healthcare expendi  tures is; however, it is plainly obvious 
to some that a boom in technology and a heightened 
practice of defensive medicine have no doubt contri-
buted. To rein in spending, therefore, we will require 
better knowledge about the eﬀ  ectiveness of existing and 
emerging diag  nostic and treatment modalities, along 
with an appro  priate system of accountability.
Although many nations have already recognized the 
importance of such research [2,3], the United States has 
only recently begun to embrace these goals with what it 
calls comparative eﬀ  ectiveness research. In 2009 the US 
Congress passed legislation (the American Recovery and 
Reinvestment Act) with $1.1 billion in research funds 
targeting comparative eﬀ   ectiveness research. Th  e US 
Institute of Medicine, at the behest of the US Congress, 
then created a priority list of comparative eﬀ  ectiveness 
research topics. To serve as a guide for their discussions, 
the Institute of Medicine described comparative eﬀ  ect-
ive  ness research as ‘the generation and synthesis of 
evidence that compares the beneﬁ  ts and harms of alter-
native methods to prevent, diagnose, treat, and monitor a 
clinical condition, or to improve the delivery of care. Th  e 
purpose of comparative eﬀ  ectiveness research is to assist 
consumers, clinicians, purchasers, and policy makers to 
make informed decisions that will improve health care at 
both the individual and population levels’ [4].
To that end, Opmeer and colleagues present a study that 
is ahead of the curve [1]. Th  ey provide an excellent 
economic follow-up to their randomized clinical trial 
evaluating on-demand versus planned relaparotomy in 
patients with severe peritonitis [5]. Th  eir initial study 
found no signiﬁ  cant diﬀ  erences in morbidity or mortality 
in the on-demand relaparotomy group as compared with 
the planned relaparotomy group. Th  ere was, however, a 
substantial reduction in the number of relaparotomies, in 
healthcare utilization, and in direct medical costs. 
Moreover, the authors have taken their economic analysis 
one step further and now, using the societal perspective, 
provide a more in-depth evaluation of the costs associated 
with these two relaparotomy strategies. Th  e authors 
examined direct medical costs (that is, hospital/intensive 
care unit admissions, therapeutic and diagnostic 
interventions, medications, and so forth), direct 
nonmedical costs (that is, travel to and from healthcare 
providers), and indirect costs (that is, loss of productivity 
due to impaired ability to work). Th   ey found substantially 
lower resource utiliza  tion in the on-demand group, 
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patients with severe perito  nitis even more convincing.
Unfortunately, this intriguing and very compelling 
analysis of a severely ill patient population raises more 
questions than it answers. New knowledge regarding the 
treatment strategies employed for many decades cannot 
aﬀ  ect signiﬁ  cant change in practice patterns overnight. 
Such studies should, however, serve as a reminder to 
physicians choosing between treatments that there may 
be other equally eﬃ     cacious, yet more cost-eﬀ  ective, 
options. Additionally, physicians should understand the 
economic impact of such decisions. Sadly, to what extent 
they use this economic information to bend their own 
cost curve is where frivolous arguments about death 
panels have arisen. Fortunately, such scare tactics are 
falling by the wayside and meaningful discussions about 
accountable care organizations and patient-centered 
medical homes are emerging [6]. Th   ese concepts rest on 
the notion that, in order to begin bending the cost curve, 
hospital and physician behaviors must be aﬀ  ected. Th  e 
most prudent strategy to achieve this is through mone-
tary incentives, where accountable care organizations 
and medical homes could serve as the lever for accounta-
bility, both ﬁ  nancial and in the quality of care delivered. 
Research, such as Opmeer and colleagues’ study, can 
serve to further inform the nuts and bolts of such 
programs, while providing invaluable information to 
physicians on the frontline of medicine.
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